Engineered Solutions Elevate Battery System Safety
6.6.2024 10:46:00 EEST | Business Wire | Press release
Oerlikon presents a full range of innovative customized safety components for Battery Electric Vehicles (BEVs), including pioneering heat shields, gas guidance systems, and cell separators.In the event of a battery fire, they improve the heat protection and electrical and mechanical strength of the batteries, which can save passengers' lives.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606775871/en/
Heat resistant parts such as Oerlikon’s high performance customizable heat shields with superior thermal and electrical insulation increase the safety of battery systems. (Image source: OERLIKON)
Thermal runaway poses a significant challenge in high-performance battery systems and can potentially cause extensive vehicle damage or endanger passengers. “Oerlikon is renowned in the automotive market for its engineering expertise and materials innovation. Now we combine carefully engineered cutting-edge heat-resistant materials with an intelligent design to create thermal insulation systems that are redefining industry standards,” said Marcus Spreckels, Head of Technology TIS.
Highly heat-resistance yet thin and lightweight
The portfolio covers all critical components, from heat shields and gas guidance components to cell separators, to address the needs of any battery system and risk level. They are highly heat-resistant, mechanically durable, and yet ultra-light and thin. They insulate the critical high-voltage infrastructure of the batteries electrically and thermally, thus reducing the likelihood of battery fires spreading to the passenger area at an early stage.
From meeting the basic regulatory standards of the UN Electric Vehicle Safety Regulation (GTR 20) and their often more stringent adoption in individual countries, to exceeding the advanced requirements with Stop/Zero TP and limp-home functionality, the components are both versatile and reliable.
No compromise: customized solutions for any requirement
Unlike other manufacturers, Oerlikon does not offer standard products. Marcus Spreckels: "We develop customized solutions in terms of material and design, taking into account the specific safety requirements of each battery concept without compromising on space or weight."
This is where Oerlikon's experience in automotive engineering comes into play: all components are 3D-moldable, so they can be optimally tailored to the design of the battery system and the vehicle, for maximum protection. Each solution is fully customized and ready to install according to individual requirements.
Combining materials science know-how and automotive experience
Oerlikon's thermal insulation solutions across all safety concepts and battery types on the market represent a new standard in the industry. With their deep knowledge in material science, Oerlikon's engineers have created heat-resistant materials with new properties. Furthermore, Oerlikon's decade-long experience in the automotive market allows customers to benefit from customized solutions from a certified manufacturer who is well-versed in the challenges associated with designing vehicles.
Series production for the entire portfolio has started at the Bremen site in the first quarter of 2024.
IATF 16949 certified and using only mica-free materials in its solutions, Oerlikon is committed not only to advancing vehicle safety, but also to environmental responsibility and ethical materials sourcing.
Visit Oerlikon at the Battery Show Europe in Stuttgart, Hall 8, Booth G85! Come by to explore our pioneering multifunctional thermal insulation solutions and meet the developers.
For interviews or more information, please contact us.
About the Oerlikon Surface Solutions Division
Oerlikon is a leading global provider of surface and additive manufacturing solutions and services. The division offers an extensive portfolio of market-leading thin-film, thermal spray and additive manufacturing technologies, equipment, components and materials. Emission reduction in transportation, maximized longevity and performance of tools and components, increased efficiency and intelligent materials are hallmarks of its leadership. Pioneering technology for decades, the division serves customers with standardized and customized solutions across a worldwide network of more than 170 sites in 37 countries.
With its technology brands – Oerlikon Balzers, Oerlikon Metco and Oerlikon AM – the Oerlikon Surface Solutions division focuses on technologies and services that improve and maximize performance, function, design, reliability and sustainability, which are innovative, game-changing advantages for customers in the automotive, aviation, tooling and general industries and in the luxury, medical, semiconductors, power generation and oil & gas markets.
The division is part of the publicly listed Oerlikon Group (SIX: OERL), headquartered in Switzerland, which has 12,600 employees and generated CHF 2.7 billion in revenue in 2023.
For more information see: www.oerlikon.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606775871/en/
Contact information
Anja Goller
Head of Marketing & Communications
Tel: +49 89 203 015 126
anja.goller@oerlikon.com
www.oerlikon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom